PuSH - Publikationsserver des Helmholtz Zentrums München

76 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Ahuja, V.* et al.: Accuracy of 1-hour plasma glucose during the oral glucose tolerance test in diagnosis of type 2 diabetes in adults: A meta-analysis. Diabetes Care 44, 1062-1069 (2021)
2.
Bizzotto, R.* et al.: Processes underlying glycemic deterioration in type 2 diabetes: An IMI DIRECT Study. Diabetes Care 44, 511-518 (2021)
3.
Blonde, L.* et al.: Durable effects of iGlarLixi up to 52 weeks in type 2 diabetes: The LixiLan-G Extension Study. Diabetes Care 44, 774-780 (2021)
4.
Bonifacio, E. et al.: An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care, DOI: 10.2337/dc20-2122 (2021)
5.
Neuwahl, S.J.* et al.: Patient health utility equations for a type 2 diabetes model. Diabetes Care 44, 381-389 (2021)
6.
Pedron, S. ; Kurz, C.F. ; Schwettmann, L. & Laxy, M.: The effect of BMI and type 2 diabetes on socioeconomic status: A two-sample multivariable mendelian randomization study. Diabetes Care 44, 850-852 (2021)
7.
Shao, H.* et al.: Trends in total and out-of-pocket payments for noninsulin glucose-lowering drugs among U.S. adults with large-employer private health insurance from 2005 to 2018. Diabetes Care 44, 925-934 (2021)
8.
Addala, A.* et al.: A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: A transatlantic comparison. Diabetes Care 44, 133-140 (2020)
9.
Garvey, W.T.* et al.: Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care 43, 1085-1093 (2020)
10.
Kahl, S.* et al.: Empagliflozin effectively lowers liver fat content in well-controlled Type 2 Diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43, 298-305 (2020)
11.
Liu, X.* et al.: Distinct growth phases in early life associated with the risk of type 1 diabetes: The TEDDY study. Diabetes Care 43, 556-562 (2020)
12.
Ochoa-Rosales, C.* et al.: Epigenetic link between statin therapy and type 2 diabetes. Diabetes Care 43, 875-884 (2020)
13.
Soldo, J.* et al.: Increased hepatic ACE2 expression in NAFL and diabetes-A risk for COVID-19 patients? Diabetes Care 43, E134-E136 (2020)
14.
Vehik, K.* et al.: Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the Teddy study. Diabetes Care 43, 2066-2073 (2020)
15.
Dawed, A.Y.* et al.: Variation in the plasma membrane monoamine transporter (PMAT, encoded in SLC29A4) and organic cation transporter 1 (OCT1, encoded in SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: An IMI DIRECT study. Diabetes Care 42, 1027-1033 (2019)
16.
Hulman, A.* et al.: Glucose measurements at various time points during the OGTT and their role in capturing glucose response patterns. Diabetes Care 42, e56-e57 (2019)
17.
Kowall, B.* et al.: Incidence rates of type 2 diabetes in people with impaired fasting glucose (ADA vs. WHO Criteria) and impaired glucose tolerance: Results from an older population (KORA S4/F4/FF4 Study). Diabetes Care 42, E18-E20:DC181473 (2019)
18.
Krischer, J.P.* et al.: Predicting islet cell autoimmunity and type 1 diabetes: An 8-year TEDDY study progress report. Diabetes Care 42, 1051-1060 (2019)
19.
Schlesinger, S.* et al.: General and abdominal obesity and incident distal sensorimotor polyneuropathy: Insights into inflammatory biomarkers as potential mediators in the KORA F4/FF4 cohort. Diabetes Care 42, 240-247 (2019)
20.
Winkler, C. et al.: Age, HLA, and sex define a marked risk of organ-specific autoimmunity in first-degree relatives of patients with type 1 diabetes. Diabetes Care 42, 1684-1691 (2019)